Under construction – not a live service
Sign in
Not yet recruitingNo phase

Physical Activity Level at Home in CMT1A Patients: Wearable Sensor Assessment

Key facts

Who runs it
University Hospital, Limoges
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
60 people, planned
Started
1 Jun 2026
Expected to end
30 Jun 2027
Type of study
Observational
Record updated
22 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Genetically confirmed diagnosis of CMT1A (PMP22 duplication on chromosomal analysis)
  • Followed at the National Reference Centre for Rare Peripheral Neuropathies (Service de Neurologie, CHU de Limoges) and/or having undergone gait analysis at the Quantified Movement Analysis Laboratory (Laboratoire d'AQM), Service de Médecine Physique et de Réadaptation, CHU de Limoges
  • Ability to walk independently (with or without walking aids)
  • Informed consent obtained
  • Affiliated to French social security system

Who cannot take part

  • Other associated neurological condition that could independently affect walking or motor activity
  • Inability to wear the sensor device (skin allergy, sensory intolerance)
  • Inability to comply with study procedures (cognitive impairment, no fixed domicile)
  • Participation in another interventional study during the same period
  • Pregnant or breastfeeding women
  • Patients under legal protection (guardianship or curatorship)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common hereditary peripheral neuropathy, affecting approximately 26,000 patients in France. It presents as chronic and progressive sensorimotor deficits predominantly affecting the distal lower limbs, with onset typically in childhood. There is currently no specific pharmacological treatment; management remains symptomatic.

Read full original descriptionShow less

This research will:

In the long run, validated wearable sensors could improve patient follow-up, personalize rehabilitation, and support the design of clinical trials for CMT1A - including trials of the novel "Nano-Cur" treatment currently under development.

The group in the trial

  • CMT1A-HOME

    Adult patients diagnosed with CMT1A followed at the National Reference Centre for Rare Peripheral Neuropathies (CHU de Limoges) and/or the Laboratoire d'AQM (Service de MPR, CHU de Limoges). Participants will undergo: (1) comprehensive in-hospital functional evaluation using the CMT-FOM scale and standard clinical assessments, and (2) home-based physical activity monitoring with ActiGraph LEAP wearable sensors over 7 days.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Study of the Relationship Between Clinical and Functional Characteristics of Patients With CMT1A Disease and Their Level of Physical Activity at Home Measured Using Portable Electronic Sensors
Record updated
22 May 2026